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Introduction
Increasing evidence indicates a protective role for cytotoxic
T lymphocytes (CTL) in the host defence against human
immunodeficiency virus (HIV). CTL reactive against HIV
antigens have been detected in persons exposed to the virus
but lacking evidence of infection. These include a small number
of female prostitutes in Africa, sexual partners of infected
persons, children born to infected mothers and health care
workers exposed to infectious body fluids (reviewed by
Rowland-Jones & McMichael, 1995). Based upon the as-
sumption that CTL induction requires endogenous synthesis of
viral proteins, these findings suggest that transient HIV
infection and virus clearance by CTL are indeed possible.
During acute HIV infection, the detection in circulation of
specific CTL coincides with the fall in viraemia that follows the
initial virus burst (Borrow et al., 1994 ; Koup et al., 1994). In the
subsequent stages, persistence of antiviral CTL may be
associated with a prolonged asymptomatic period, whereas
their decline is usually coincident with disease progression
(Klein et al., 1995). Nevertheless, a few patients with advanced
disease may maintain relatively strong CTL responses against
the core HIV Gag protein (Geretti et al., 1996). Studies on the
relationship between virus load and CTL responses in
chronically infected patients have also yielded conflicting
results, as both direct (Ferbas et al., 1995) and inverse (Klein et
al., 1995) correlations have been reported. While further work
is needed to clarify such discrepancies, it is clear that antiviral
CTL responses can only be interpreted in the framework of the
dynamics of virus replication, recognition and clearance of
infected cells, and virus attempts to evade immune surveillance.
Infection of macaques with simian immunodeficiency virus
(SIV) offers a valuable model for studying the complex
interaction between lentiviruses and the host immune system.
The aim of this review is to outline how this model has
contributed to our understanding of the role of CTL in the
control of lentiviral infections, and how its full potential may
be exploited in the future.
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General aspects of SIV infection of macaques
SIV of macaques (SIVmac) was first isolated in 1985 from
animals held in captivity in the United States. Macaques,
however, are not natural hosts of the virus. It is believed that
cross-species transmission from sooty mangabeys, which are
healthy natural carriers of SIV (SIVsm), was the source of
infection. Fighting and biting among animals co-housed in
outdoor corrals was the most likely route of horizontal
transmission (Gardner, 1996). SIVmac shares with HIV many
biological and structural features, including its tropism for the
CD4 receptor and CCR5 co-receptor (Chen et al., 1997), a
similar genomic organization and extensive genetic homology.
The virus establishes persistent infection in macaques and
causes an immunodeficiency syndrome closely resembling
human AIDS. As in humans, prominent features of the disease
include CD4+ cell loss, constitutional symptoms, lymphaden-
opathy, skin and neurological disorders, opportunistic in-
fections and neoplasias. Although the average time to disease
is 1–2 years, the course of infection varies considerably among
macaques. Even after infection with the same viral molecular
clone, some animals rapidly develop disease and die within
months, whereas others may remain asymptomatic for a few
years, thus resembling long-term non-progressors with HIV
infection. This variability, combined with the opportunity to
define parameters of infection such as strain, dose and route of
virus inoculation, may prove valuable for clarifying the role of
CTL immunity in lentivirus containment.
Detection of SIV-specific CTL
Target cells
SIV-specific CTL responses are currently measured against
autologous B lymphoblastoid cell lines (B-LCL) immortalized
by herpesvirus papio. After infection with recombinant
vaccinia virus vectors (rVV) encoding SIV proteins, these cells
express endogenously processed antigen in the context of
MHC class I molecules. The use of rVV expressing different
regions of the SIV genome has shown that SIV-specific CTL
target both structural and regulatory viral proteins, although
the strength and magnitude of the response vary among
animals (Venet et al., 1992 ; Geretti et al., 1997 a). Alternatively,
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B-LCL can be sensitized for lysis by incubation with short
synthetic viral peptides that bind directly to MHC class I
molecules on the cell surface, thus allowing the definition of
epitope specificities.
Effector cells
In vitro restimulation has almost universally been required
to amplify SIV-specific CTL responses to detectable levels. As
an interesting exception, direct cytotoxicity against the
envelope protein (Env), Gag and the regulatory protein Nef
has been recently observed with intestinal intraepithelial
lymphocytes of two macaques infected with SIVmac
#&"
(Coudel-Courteille et al., 1997). One of the animals showed
signs of advanced disease, including a marked colitis. Although
a high proportion of intestinal intraepithelial lymphocytes
express the CD8 marker, the exact nature and function of the
activated intestinal effector cells, and their contribution to host
defence or immunopathogenesis, remain to be determined. The
same authors found little or no evidence of direct cytotoxicity
in peripheral blood, spleen and lymph nodes. This is in line
with the observation that the frequencies of circulating CTL
precursors (CTLp) detected in SIV-infected or vaccinated
macaques are generally lower than those often measured in
asymptomatic HIV-infected adults (Geretti et al., 1997a). While
the requirement for appropriate methods of CTLp restimu-
lation may explain the apparent lack of CTL induction in some
vaccine studies, it also highlights the need for standardized
assays which would facilitate comparison of different exper-
iments, often including only small numbers of animals.
One successful method for the expansion in vitro of HIV- or
SIV-specific CTLp is based on stimulation with paraform-
aldehyde-fixed autologous B-LCL infected with rVV express-
ing HIV or SIV antigens (Van Baalen et al., 1993). Compared
with non-specific methods of stimulation, this approach
enhances CTL detection in macaques by inducing selective
CTL expansion, with reduced interference from background
lysis (Geretti et al., 1997a). Cell culture under limiting dilution
conditions appears to increase further the sensitivity of CTL
measurement, as it allows CTLp detection, albeit at low
frequencies, in macaques lacking significant responses in
standard bulk CTL assays (Geretti et al., 1997 a). Autologous
blasts infected with SIV have also been used successfully as
stimulator cells (Gallimore et al., 1995). Alternatively, synthetic
peptides spanning defined regions of the SIV genome can be
used to stimulate the growth of epitope-specific CTL.
Should vaccine-induced CTL prevent or limit
virus replication?
Early vaccine studies in macaques aimed primarily at
preventing infection through the induction of virus-neutral-
izing antibodies. As a result, a protective role of CTL in some
of the successful vaccination strategies reported, such as those
based upon live attenuated SIV vaccines (reviewed by
Ruprecht et al., 1996), can only be hypothesized.More recently,
the prevailing view that it may be desirable for a vaccine to
prevent disease if not infection, and the appreciation that SIV
infection of macaques provides a valuable model for studying
HIV pathogenesis, coupled with the development of reliable
means of detecting SIV-specific CTL, have drawn considerable
attention to antiviral cell-mediated immunity.
SIV Env-, Gag- or Nef-specific CTL have been induced in
macaques through several immunization strategies, including
live attenuated viruses (Cranage et al., 1997), proteins either
expressed by live vectors such as rVV (Gallimore et al., 1995 ;
Kent et al., 1996), incorporated into iscoms (Hulskotte et al.,
1995) or adjuvanted by QS-21 saponin (Newman et al., 1994),
non-infectious virus-like particles (Klavinskis et al., 1997),
peptides in various formulations (Bourgault et al., 1994 ;
Hulskotte et al., 1995 ; Yasutomi et al., 1995) and DNA
plasmids (Lu et al., 1996). In those studies that have tested the
outcome of subsequent challenge, the detection of vaccine-
induced CTL has usually failed to predict complete resistance
to infection. In one early report, vaccine-induced CTL against
pC11, a well-defined epitope in Gag, failed to protect macaques
from intravenous challenge with SIV Macaca nemestrina
(SIVmne) (Yasutomi et al., 1995). The induction of relatively
low frequencies of CTLp of limited specificity, and the absence
of antibodies, were believed to have contributed to the lack of
protection. However, in a subsequent report, immunization
with Env- and Gag-iscoms and three lipopeptides spanning the
central region of Nef induced both virus neutralizing antibodies
and Env-, Gag or Nef-specific CTLp, but similarly failed to
protect macaques from intravenous challenge with
SIVmac
$#H-J&
(Hulskotte et al., 1995). Furthermore, no cor-
relation was found between the frequencies of SIV-specific
CTLp detected before challenge and the levels of cell-
associated virus load measured after infection. It is of note,
however, that CTLp frequencies were in most cases below
26}10' peripheral blood mononuclear cells (PBMC). Never-
theless, even the animal with a relatively high frequency of
Env-specific CTLp (105}10' PBMC) was not protected from
infection. Recently, intravenous, intramuscular and gene gun
inoculations of SIV DNA plasmids have produced similar
results : despite the induction of virus neutralizing antibodies
and Env-specific CTL, no protection was induced against
intravenous challenge with SIVmac
#&"
(Lu et al., 1996).
Although disappointing, these findings are consistent with
the view that CTL may not be able to prevent or control SIV
infection, unless stringent qualitative and quantitative require-
ments are met. This finds indirect support in the observation
that macaques immunized with whole inactivated SIVmac
$#H
,
and protected from intravenous challenge with cell-associated
virus, share the Mamu-A26 MHC class I allele with the donor
of the infected cells (Osterhaus et al., 1992 ; Heeney et al.,
1994). Mamu-A26 positive animals also behave as long-term
survivors (Bontrop et al., 1996), suggesting that gene products
of this allele may be correlated with the ability to mount
protective CTL responses against SIV. More direct evidence of
EBG
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a protective role of defined CTL subpopulations is provided by
a study of macaques immunized with SIV Nef rVV (Gallimore
et al., 1995). Although six of seven animals became infected
upon intravenous challengewith SIVmac
$#H-J&
, the frequencies
of vaccine-induced Nef-specific CTLp measured before chal-
lenge were inversely correlated with the levels of virus load
measured after infection. In addition, the animal with the
highest CTLp frequency was protected from infection. As
these promising findings indicate, the protective role of CTL
responses targeting regulatory proteins expressed early during
the virus replication cycle deserves further investigation.
Recent findings appear to support the concept that
protective CTL may limit rather than completely prevent virus
replication. Vaccinated macaques lacking both detectable virus
and antibody responses after either intravenous or intrarectal
challenge with SIVmne showed CTL responses against SIV
proteins present in the challenge virus but not in the vaccine
(Kent et al., 1996). Similarly, macaques immunized with Env-
iscoms lacked both detectable virus and anamnestic antibody
responses after intravenous challenge with a chimeric simian–
human immunodeficiency virus (SHIV), but had CTLp against
antigens other than Env, including the non-virion regulatory
proteins Rev and Tat (E. G. J. Hulskotte, unpublished). These
data indicate that CTL responses provide a highly sensitive
marker of transient or low-level virus replication. It is tempting
to speculate that similar silent or abortive infections may have
remained undetected in some of the early vaccine studies.
What is the role of antiviral CTL in mucosal
immunity?
As most HIV infections are acquired by mucosal routes,
current efforts are directed at inducing immune responses that
may prevent or limit virus spread after mucosal exposure. The
SIV model offers the opportunity to explore issues related to
mucosal immunity and infection that are difficult to address in
humans. Indeed, evidence that protection from sexually
transmitted SIV and, by inference, HIV may be induced by
effectively stimulating genital and systemic antiviral CTL is
increasing. In female macaques inoculated intravaginally with
SIVmac
#&"
, at least some (1 in 2425 to 1 in 26686) of the CD8+
cells recovered from the vaginal epithelium are SIV-specific
CTLp directed against Env or Gag. In line with the view that
progressive CTL compartmentalization occurs during per-
sistent infection, the frequencies of genital CTLp are higher in
chronically infected monkeys than in animals with recent
infection (Lohman et al., 1995). SIV-specific CTL have also been
detected in both peripheral blood and gut-associated lymph
nodes of macaques infected intravenously with live attenuated
SIVmac
C)
, and resistant to intrarectal challenge with either
SIVmac
$#H-J&
or SHIV (Cranage et al., 1997). Furthermore,
inoculation of macaques with SIV p27 :Ty virus-like particles
by either the rectal-oral and vagino-oral route, or subcutaneous
immunization targeting the iliac lymph nodes, has induced
specific CTL in the rectal and cervico-vaginal mucosa, as well
as in regional lymph nodes, spleen and peripheral blood
(Klavinskis et al., 1997). Finally, intra-vaginal inoculations with
attenuated SHIV have induced at least partial resistance to
intravaginal challenge with pathogenic SIVmac
#$*
(Miller et al.,
1997). Although the presence of SIV-specific CTL in the
genital tract was not determined in this study, protected
animals had circulating Gag-specific CTL at the time of
challenge, with or without specific antibodies in genital
secretions. To explain the generation of local and systemic
primary immune responses upon vaccine delivery to mucosal
sites, antigen uptake by resident dendritic cells is hypothesized,
followed by their migration to regional lymph nodes where
naive T lymphocytes are stimulated. These would then enter
the circulation and migrate to the genital site, where they may
be restimulated upon re-exposure to the antigen, thus
providing a first line of defence against sexually transmitted
viruses.
What is the relationship between SIV-specific
CTL and virus replication?
Kinetics studies have shown that the detection of Gag- or
Nef-specific CTL by week 1 or 2 after intravenous SIV
infection is coincident with the decrease in virus load and p26
antigenaemia that follows the initial virus burst (reviewed by
Letvin et al., 1994). In the early phase of infection, virus load
and SIV-specific CTL responses show similar kinetics in
peripheral blood and lymph nodes. In contrast, during chronic
infection, virus sequestration within lymphoid organs (Chak-
rabarti et al., 1994) is mirrored by CTL compartmentalization
to the sites of infection (A. M. Geretti, unpublished). These
observations are consistent with CTL being the effector cells of
the in vivo immune response against SIV. Further support for a
protective role of antiviral CTL comes from the observation
that macaques with strong CTL responses against multiple SIV
antigens, including the regulatory proteins Nef, Rev and Tat,
remained free of disease for at least 2 years after intravenous
infection with SIVmac
#&"
. In contrast either absent, transient or
weak CTL responses were observed in animals rapidly
progressing to overt disease (Venet et al., 1992). Preliminary
findings also indicate that the detection of CTL responses
against Rev and Tat in the early phase of infection may be
associated with effective virus containment and long-term
survival in both HIV-infected humans (Van Baalen et al., 1997)
and SIV-infected macaques (A. M. Geretti, unpublished). These
data are again in agreement with the hypothesis that CTL
targeting early gene products may be effective in virus control
before release of progeny virus occurs. Another point of
interest is that the same CTL may also recognize latently
infected cells that, although not actively producing virus, are
known to express multiple spliced viral messenger RNAs
encoding the regulatory proteins Nef, Rev and Tat (Seshamma
et al., 1992 ; Embretson et al., 1993).
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Fig. 1. Kinetics of circulating SIV-specific CTL precursors (CTLp) in macaques infected intravenously with SIVmac32H-J5. After
the initial burst of virus replication, three monkeys (A) lost evidence of either culturable virus or PCR-detectable provirus in
peripheral blood, while maintaining low-level virus reservoirs in spleen and lymph nodes; these animals remained asymptomatic
with stable CD4+ cell counts throughout 22 months of observation. Three other monkeys had persistent virus in peripheral
blood and high virus load in lymphoid organs : one (B) developed AIDS 18 months after infection, whereas two others (C)
remained asymptomatic but over time showed a significant CD4+ cell decline. CTLp frequencies were measured by limiting
dilution assays. Autologous B-LCL infected with rVV expressing SIV antigens were used in vitro as stimulator and target cells.
The cumulative frequencies of circulating SIV-specific CTLp, after reaching a plateau, declined significantly in the three
macaques lacking detectable virus in peripheral blood (A) and in the animal which progressed to overt disease (B), but were
maintained in the two asymptomatic macaques with persistent infection in peripheral blood (C).
The relatively low frequencies of SIV-specific CTLp usually
detected in SIV-infected macaques seem in contrast with the
strong CTL responses often detected in asymptomatic HIV-
infected persons. Besides the influence of host genetic factors,
or the effects of progressive immunodeficiency, relatively low
CTLp frequencies may reflect a low degree of antigenic
stimulation in vivo, due to rapid down-regulation of SIV
replication after infection. Consistent with this view, high
CTLp frequencies can be detected occasionally in animals with
a high virus load in their PBMC (Geretti et al., 1997a).
Conversely, the frequencies of circulating SIV-specific CTLp
may decline significantly over time in asymptomatic SIV-
infected macaques lacking detectable virus in PBMC and
showing low-level virus reservoirs in lymphoid organs (Fig. 1 ;
A. M. Geretti, unpublished). In view of these findings, it is not
surprising that the degree of protection conferred by live
attenuated SIV vaccines, and the strength of the Env- and Gag-
specific CTL responses they induce, appear to be inversely
correlated with the level of virus attenuation (Lohman et al.,
1994). These data have direct implications for vaccine designs
aimed at inducing long-lasting protective CTL responses : a
successful vaccine will need to achieve a difficult balance
between safety, which is dependent upon a high degree of
attenuation, and efficacy, which appears directly related to the
ability of the virus to replicate.
Are virus-specific CTL deleterious to the
host?
It has been suggested that in a physiological attempt to
eradicate persistent infection, CTL may also induce patho-
logical changes deleterious to the host. This is supported by
the finding that HIV-specific CTL are present in both the
bronchoalveolar lavage of AIDS patients with lymphocytic
alveolitis and in the cerebrospinal fluid (CSF) of patients with
AIDS dementia complex (reviewed by Zinkernagel, 1995). The
detection of SIV-specific CTL in the skin rash of SIV-infected
macaques (Yamamoto et al., 1992) also suggests a role for CTL
in mediating tissue damage. SIV-specific CTL have been also
detected in the CSF and brain of SIV-infected macaques as
early as 1 week after infection and concomitant with the
detection of virus (Von Herrath et al., 1995). Interestingly,
different SIV proteins were targeted by CTL recovered from
the brain, CSF and peripheral blood, suggesting that these can
be separate compartments in SIV infection. As these interesting
data indicate, the SIV model provides an excellent system to
explore further the role of CTL in HIV-associated neurological
disorders.
Can SIV variants escape CTL recognition?
Selection of mutant viruses resistant to specific CTL may be
proposed as one mechanism whereby highly variable viruses
such as HIV or SIV escape from immune recognition. Single
amino acid substitutions within CTL epitopes can abrogate
recognition by affecting either MHC binding or T cell receptor
(TCR) interaction (Rothbard et al., 1989), whereas mutations
within epitope flanking regions may reduce presentation by
affecting peptide processing and transport (Eisenlohr et al.,
1992). Recent studies also suggest that mutated epitopes may
arise, which still interact with the TCR, but inhibit CTL
function by inducing T cell anergy, or by showing partial
agonistic or antagonistic activity (reviewed by Klenerman et
al., 1996). In this case, even virus variants that do not become
EBI
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the predominant viral species may affect immune surveillance,
as they can block CTL recognition of viruses that do not
contain mutated epitope sequences. Finally, rapid virus evol-
ution and strong antigenic stimulation may also favour immune
evasion by causing CTL exhaustion (Von Boehmer, 1993).
Although mutant viruses which are resistant to CTL have
been detected in persons infected with HIV (reviewed by
Koup, 1994 ; Koenig et al., 1995 ; Borrow et al., 1997 ; Goulder
et al., 1997), and despite evidence that multiple mechanisms
may be operative in HIV attempts to escape recognition
(Couillin et al., 1994), the biological relevance of these findings
remains somewhat controversial. The fact that HIV-infected
persons, or SIV-infected macaques, generally mount CTL
responses against multiple viral antigens suggests that despite
the loss of CTL recognition of one epitope, complete evasion
from immune surveillance should be a rare occurrence.
Nevertheless, qualitative aspects of antiviral CTL, such as the
nature of the targeted epitope (Moskophidis & Zinkernagel,
1995) and the affinity of effector cell–target cell interactions
(Tsomides et al., 1994) may be crucial determinants of effective
CTL pressure. It is therefore conceivable that under stringent
circumstances, strong CTL responses targeting key epitopes
may promote selection of virus mutants which, at least
temporarily, can evade immune recognition. The finding that
the presence of strong CTL responses against Env is associated
with pronounced HIV genetic heterogeneity (Wolinsky et al.,
1996) appears to support this view.
The effects of CTL pressure on SIV evolution have so far
received limited attention. In a study of macaques infected with
SIVmac
#&"
, the presence of strong p11C-specific CTL responses
was associated with the detection of amino acid mutations
within the CTL epitope (Chen et al., 1992). Although two of
fourmutated epitope sequences were recognized less efficiently
than the prototype sequence, statistical analysis failed to
indicate a higher rate of mutations in the epitope compared
with other regions of Gag, and selection of the mutated viruses
could not be demonstrated.
Infection of macaques with molecular clones of SIV may
help to clarify the significance of virus escape in pathogenesis
and disease progression, as any mutation detected in the viral
genome must have originated during the course of the
infection. In a long-term non-progressor macaque infected
with the molecular clone SIVmac
$#H-J&
, the detection of ‘high
affinity ’ immunodominant CTL targeting a 9-mer epitope in
Gag designated p26A.5 (Geretti et al., 1997b), coincided with
the emergence of a variant virus carrying a mutated epitope
sequence (A. M. Geretti, unpublished). Surprisingly, the
mutated sequence was detected in the spleen, where it had
uniformly replaced the challenge virus, but not in peripheral
blood or lymph nodes. One explanation for this finding is that
co-existence of viral expression and CTL expansion in splenic
white pulp creates a highly favourable microenvironment for
immunological pressure (Cheynier et al., 1994). The absence of
epitope mutations in animals lacking detectable p26A.5-
Fig. 2. Different patterns of epitope-specific CTL recognition. In a long-
term non-progressor macaque infected with the molecular clone
SIVmac32H-J5, the detection of CTL targeting a 9-mer epitope in Gag
designated p26A.5 (amino acids 242–250 of p26) coincided with the
emergence in the spleen of a variant virus carrying an aspartic acid to
glutamic acid substitution (D!E) at position 244. Short-term CTL lines
generated in vitro by stimulation of PBMC with a peptide representing the
prototype p26A.5 epitope were tested for their ability to lyse chromium-
labelled B-LCL pulsed with either the prototype p26A.5 peptide, or a
variant peptide carrying the mutated epitope sequence. Four patterns of
reactivity were identified : most (38 of 56) CTL lines (e.g. A01) did not
recognize the variant peptide even at the highest peptide concentration
tested (100 lM); eight (e.g. C12) recognized the prototype peptide with
higher efficiency than the variant peptide ; seven (e.g. A05) recognized
both the prototype and the variant peptide with a similar efficiency ; and
three (e.g. F09) recognized the variant peptide with higher efficiency than
the prototype peptide.
specific CTL favours immunological pressure over simply
growth advantage as the cause of virus mutation. The variant
virus escaped recognition by most, but not all p26A.5-specific
CTL (Fig. 2). The latter observation suggests a certain
redundancy of CTL responses targeting the same epitope, also
described for pC11-specific CTL (Shen et al., 1994 ; Chen et al.,
1996), which may represent a first-line safeguard mechanism
against emerging virus variants. Remarkably, CTL sub-
populations targeting the variant sequence also localized
preferentially in the spleen. The low virus load detected in this
compartment suggests effective virus containment. However,
the idea that a variant virus with even a slight advantage might
have eventually replaced the challenge virus also in other
compartments and gradually affected the control of the
infection remains a valid hypothesis.
Conclusions
Over the past decade, the macaque model of SIV infection
has provided significant new information on the host–virus
interplay taking place during the course of lentiviral infections.
Increasing evidence indicates a role for antiviral CTL in the
containment of SIV replication, and supports the view that the
quality of antiviral CTL is as important as their quantity in
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determining both the outcome of infection and the course of
the disease. It is now believed that the ability to induce
antiviral CTL that would limit, if not completely prevent virus
spread, particularly after mucosal exposure, is an important
prerequisite of an effective HIV vaccine. The concept that the
design of such a vaccine will require improved understanding
of what may constitute a protective CTL response is also now
widely accepted. The SIV model offers valuable opportunities
to better understand the mechanisms of lentivirus-induced
disease and to clarify the basis for protective immunity.
Hopefully, it will fulfil its promise – helping the development
of a successful vaccination strategy against HIV.
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